Sami I R, Piazza F M, Johnson S A, Darnell M E, Ottolini M G, Hemming V G, Prince G A
Dept. of Pulmonary Medicine, Children's National Medical Center, Washington, DC 20010.
J Infect Dis. 1995 Feb;171(2):440-3. doi: 10.1093/infdis/171.2.440.
The cotton rat model was used to test whether systemically administered immunoglobulin could protect nasal tissues against low challenge doses of respiratory syncytial virus (RSV). Animals were pretreated by intraperitoneal injection of human immunoglobulin with moderate (1:2226) or high (1:15,000) neutralizing antibody titers to RSV (day 0), challenged intranasally with RSV Long at doses ranging from 10(1) to 10(5) pfu (day 1), and sacrificed for virus titration (day 5). Pretreatment with moderate-titer immunoglobulin effected complete or near complete nasal protection against low to moderate (10(1)-10(3) pfu) RSV challenge doses and a significant reduction in nasal RSV titers at high (10(4)-10(5) pfu) challenge doses. Pretreatment with high-titer immunoglobulin effected near complete nasal protection at an RSV challenge dose of 10(3) pfu and highly significant and significant reductions in nasal RSV titers at challenge doses of 10(4) and 10(5) pfu, respectively. Immunoprophylaxis effected complete or near complete pulmonary protection at all RSV challenge doses.
采用棉鼠模型来测试全身给药的免疫球蛋白是否能保护鼻组织免受低剂量呼吸道合胞病毒（RSV）的攻击。动物于第0天腹腔注射具有中等（1:2226）或高（1:15000）RSV中和抗体效价的人免疫球蛋白进行预处理，于第1天经鼻用10¹至10⁵ pfu剂量范围的RSV Long毒株攻击，并于第5天处死用于病毒滴度测定。中等效价免疫球蛋白预处理对低至中等（10¹ - 10³ pfu）RSV攻击剂量实现了完全或近乎完全的鼻保护，对高（10⁴ - 10⁵ pfu）攻击剂量的鼻RSV滴度有显著降低。高效价免疫球蛋白预处理在RSV攻击剂量为10³ pfu时实现了近乎完全的鼻保护，在攻击剂量为10⁴和10⁵ pfu时，鼻RSV滴度分别有极显著和显著降低。免疫预防在所有RSV攻击剂量下均实现了完全或近乎完全的肺保护。
